INTRODUCTION TO LOW-LEVEL LASER THERAPY (LLLT) TECHNOLOGY
LLLT (Low level laser therapy) is a painless, sterile, non-invasive, drug-free treatment which is used to treat a variety of pain syndromes, injuries, wounds, fractures, neurological conditions and pathologies. Laser therapy can be used any time a patient requests or needs a drugless procedure for the control of pain, when conventional therapies have been ineffective, or when the acceleration of healing from injuries is desired.
- Biostimulation, including improved metabolism & increased cell metabolism
- Improved blood circulation and vasodilatation
- Analgesic effect
- Anti-edematous effects Anti-inflammatory and
- Stimulation of wound healing
- Relieves acute and chronic pains
- Increases the speed, quality and tensile strength of tissue repair
- Increases blood supply
- Stimulates the immune system
- Stimulates nerve function
- Develops collagen and muscle tissue
- Helps generate new and healthy cells and tissue
- Promotes faster wound healing and clot formation
- Reduces inflammation
The MLA830 is a GaAlA Laser that has wavelength of 830 nm with a power output of 90 mw. At this wavelength and power the ML830® Laser has a penetration of approximately 5 cm or 2 inches.
It is not an accident that the Microlight Corporation of America chose & patented the 830nm technology for its ML830®. There are 30+ years of clinical studies that proved the 830nm range is the optimal wave-length. No other Low-Level Laser offers this superior amount of penetration of tissue!
GENERAL MOTORS DOUBLE BLIND STUDY
As further background, General Motors had serious problems with Carpal Tunnel Syndrome among its workers. GM responded by conducting a 36-week double-blind study, using the ML830® to see if non-invasive conjunctive therapy would help. Among the 166 afflicted GM workers who entered the program, those treated with the ML830® laser showed significant improvement in grip strength and range of motion when compared to other GM workers who were treated with placebo lasers.
A prominent medical school in Houston conducted a similar double-blind study on CTS in 1998 that showed a 70% improvement after conjunctive therapy using the ML830® among those patients in the active group.